ADD ANI AS A TRUSTED SOURCE
googleads
Menu
Asia

Oman approves Covaxin COVID-19 vaccines for travel without quarantine

Muscat [Oman], October 27 (ANI): The Government of the Sultanate of Oman on Wednesday added Indian-made Covaxin to the approved list of COVID-19 vaccines for travel to the country without quarantine.

ANI Oct 27, 2021 21:12 IST googleads

Representative Image.

Muscat [Oman], October 27 (ANI): The Government of the Sultanate of Oman on Wednesday added Indian-made Covaxin to the approved list of COVID-19 vaccines for travel to the country without quarantine.
"COVAXIN has now been added to the approved list of COVID-19 vaccines for travel to Oman without quarantine. This will facilitate travellers from India vaccinated with COVAXIN," tweeted the Embassy of India in Muscat.
"All passengers from India who have received two doses of Covaxin at least 14 days before the estimated arrival date will now be able to travel to Oman without the requirement of quarantine. All other COVID-19 related requirements/conditions, such as pre-arrival RT-PCR test shall be applicable for such passengers," read the press release of the Indian Embassy.
This notification will significantly ease travel to Oman for Indian nationals who have taken Covaxin. Passengers who have taken AstraZeneca/Covishield are already permitted to travel to Oman without quarantine.
Covaxin, India's first indigenous COVID-19 vaccine, is developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research.
Meanwhile, the World Health Organisation (WHO) has said that the Technical Advisory Group (TAG) for Emergency Use Listing has decided that additional clarifications from the manufacturer are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine.
The UN health body said that the TAG expects to reconvene for the final risk-benefit assessment on November 3.
Bharat Biotech has been submitting data to WHO on a rolling basis and submitted additional information at the UN health body's request on September 27.
Earlier this month, WHO chief scientist Dr Soumya Swaminathan had said that the UN health body's technical advisory group will meet on October 26 to consider Emergency Use Listing (EUL) for Covaxin.Last week, WHO had said a vaccine recommended by it for emergency use must be evaluated thoroughly. (ANI)

Get the App

What to Read Next

Asia

India consistently supported Maldives in crisis: Mohamed Nasheed

India consistently supported Maldives in crisis: Mohamed Nasheed

He highlighted India's role as a "first responder" for the Maldives, emphasising that India's support during critical periods has been fundamental to the stability and security of the island nation.

Read More
Middle East

Oman Air cancel multiple routes amid regional airspace disruption

Oman Air cancel multiple routes amid regional airspace disruption

Oman Air confirmed that flights to and from Amman (AMM), Dubai (DXB), Bahrain (BAH), Doha (DOH), Dammam (DMM), Kuwait (KWI), Copenhagen (CPH), Baghdad (BGW), and Khasab (KHS) are cancelled until March 22.

Read More
Asia

Policy delays leave Pakistan short of critical medicines

Policy delays leave Pakistan short of critical medicines

Pakistan faces a severe shortage of life-saving medicines, including cancer drugs and vaccines, due to government delays in notifying official prices. While global supply remains stable, regulatory hurdles have stalled legal imports, raising concerns over patient survival and the potential rise of unregulated, counterfeit medicines.

Read More
Middle East

WHO says, "Public health risks are soaring"

WHO says,

The WHO has called on all parties to protect civilians and advocated that Peace remains the best medicine.

Read More
Middle East

Oman's Salalah oil facilities struck

Oman's Salalah oil facilities struck

Drones struck fuel tanks in the port, Oman TV reported. No damage to merchant vessels was reported, Ambrey said.

Read More
Home About Us Our Products Advertise Contact Us Terms & Condition Privacy Policy

Copyright © aninews.in | All Rights Reserved.